Ionis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad
California
92010
United States
Tel: 760-931-9200
Website: http://www.ionispharma.com/
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc., located in the North San Diego County city of Carlsbad, was founded in 1989 to create advanced, novel medicines to treat complex and challenging diseases. We are the pioneer in the discovery and development of antisense drugs with more than 1300 patents.
Ionis is a challenging, motivating and rewarding environment designed to foster innovation and scientific excellence. Our founding goals have changed little in over 27 years and our success is a direct result of our outstanding employees. We are interested in bringing together individuals with different skill sets into this creative environment to be part of a productive team. Join us and experience our unique culture while you develop and expand your career.
See Collaborations
733 articles with Ionis Pharmaceuticals, Inc.
-
Waylivra was rejected by the FDA last year but gained approval in Europe in May. The publication of final Phase III data in the New England Journal of Medicine could support a potential bid for regulatory approval in the U.S.
-
New England Journal of Medicine Publishes Results from Pivotal Study of WAYLIVRA® (volanesorsen) in Patients with Familial Chylomicronemia Syndrome
8/7/2019
Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc., announced that the final study results from the Phase 3 APPROACH study evaluating WAYLIVRA® (volanesorsen) in patients with familial chylomicronemia syndrome (FCS) were published in the August 8th issue of The New England Journal of Medicine (NEJM).
-
Ionis Reports Second Quarter 2019 Financial Results
8/7/2019
Ionis Pharmaceuticals, Inc. reported its financial results for the second quarter and year-to-date 2019 and recent business highlights.
-
Ionis Pharmaceuticals to hold second quarter 2019 financial results webcast
7/30/2019
Webcast scheduled for Wednesday, August 7th at 11:30 a.m. Eastern Time
-
Ionis Pharmaceuticals to present at the BMO Prescription for Success Healthcare Conference
6/18/2019
Ionis Pharmaceuticals, Inc., the leader in antisense therapeutics, announced that management will present a company overview at the BMO Prescription for Success Healthcare Conference at 9:20 a.m. ET on Tuesday, June 25, 2019 in New York, NY.
-
Ionis announces appointment of Joan E. Herman to its board of directors
6/12/2019
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced the appointment of a new member to its board of directors effective immediately – Joan E. Herman, MBA, MS, president and chief executive officer of Herman and Associates, LLC
-
Ionis Pharmaceuticals to provide corporate update and 30-year retrospective at its 2019 Annual Meeting of Stockholders
6/6/2019
Ionis Pharmaceuticals, Inc. announced that Stanley T. Crook, M.D., Ph.D., chairman of the board and chief executive officer, will present a general corporate update and 30-year retrospective in conjunction with its 2019 Annual Meeting of Stockholders and Open House on Thursday, June 6 at 2:10 p.m. Pacific Time in Carlsbad, CA.
-
Ionis reports first quarter 2019 financial results
5/9/2019
Ionis Pharmaceuticals, Inc. reported its financial results for the first quarter of 2019 and recent business highlights.
-
Ionis launches new corporate brand that reflects company's industry-leading innovation and unique culture of saying "yes" to patients
5/6/2019
Ionis Pharmaceuticals, Inc. unveiled its new corporate brand in a campaign inspired by its unique culture and history of developing transformative therapies for seemingly untreatable diseases.
-
Positive clinical data at AAN 2019 reinforces Ionis' commitment to delivering life-changing medicines to patients with neurological diseases
5/1/2019
Twelve presentations highlighting transformational medicines for SMA, hATTR, Huntington's disease, ALS, prion disease and others
-
Ionis Pharmaceuticals to hold first quarter 2019 financial results webcast
4/25/2019
Webcast scheduled for Thursday, May 9th at 11:30 a.m. Eastern Time
-
Ionis Pharmaceuticals to Provide Corporate Update at 2019 Annual Meeting of Stockholders
4/8/2019
Ionis Pharmaceuticals, Inc. announced that management will present a general corporate update in conjunction with its 2019 Annual Meeting of Stockholders and Open House on Thursday, June 6 at 2:10 p.m. Pacific Time in Carlsbad, CA.
-
Ionis announces appointment of Brett P. Monia Ph.D. to its board of directors
3/25/2019
Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, announced that Brett P. Monia, Ph.D., has been appointed to the company's board of directors.
-
Biotech and pharma companies from across the globe share data and news in a weekly roundup.
-
PTC to Expand Product Portfolio in Latin America with WAYLIVRA™
3/4/2019
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its partner, Akcea Therapeutics, affiliate of Ionis Pharmaceuticals, received a positive opinion for WAYLIVRA™ by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA
-
Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen)
3/1/2019
Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending conditional marketing authorization for WAYLIVRA
-
Akcea® Recognizes Rare Disease Day Through Efforts to Increase Awareness of Hereditary Transthyretin Amyloidosis and Familial Chylomicronemia Syndrome
2/28/2019
Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced the company’s support for Rare Disease Day 2019 for patients living with hereditary transthyretin (hATTR) amyloidosis and familial chylomicronemia syndrome (FCS) and their caregivers, including bringing several of them together to participate in a live panel discussion related to their disease.
-
Ionis Exceeds 2018 Financial Guidance
2/27/2019
Ionis Pharmaceuticals, Inc. reported financial results for the fourth quarter and full year 2018 and reviewed highlights of its successful year.
-
AKCEA-APO(a)-LRx Advances as Leading Pharmaceutical Company Exercises Option to License
2/25/2019
Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that Novartis has exercised its option to license AKCEA-APO(a)-LRx, a drug to treat patients with elevated levels of lipoprotein(a), or Lp(a), and established cardiovascular disease (CVD). AKCEA-APO(a)-LRx, referred to by Novartis as TQJ230, was discovered by Ionis and co-developed by Akcea and Ionis.
-
Ionis Pharmaceuticals to Hold 2018 Financial Results Webcast
2/13/2019
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, February 27th at 11:30 a.m. Eastern Time to discuss its 2018 financial results and report on pipeline and business progress.